ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
Therapy With Letrozole and hCG in Male Hypogonadism Induced by Illicit Use of AAS
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 248747" data-attributes="member: 13851"><p>[URL unfurl="true"]https://clinicaltrials.gov/ct2/show/NCT05205837[/URL]</p><p></p><h3>A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial</h3><p></p><p><strong>Brief Summary</strong></p><p></p><p><em>The overall objective of this randomized trial is to investigate the effects of treatment of AAS- induced male hypogonadism with combined therapy of letrozole and hCG compared with placebo on reproductive hormone levels, adherence to cessation of AAS use, fertility, cardiac function, and quality of life.</em></p><p></p><p></p><p><strong>Detailed Description</strong></p><p></p><p><em>A randomized, double-blinded, clinical, placebo-controlled trial enrolling 60 male illicit AAS users with documented AAS-induced hypogonadism after a period > 12 weeks of AAS cessation or a negative urine AAS doping test. Participants will be randomized to two study groups; 24 weeks of treatment with either tablet letrozole (femar®) initial dose of 2.5 mg each day versus tablet placebo. After an initial treatment period of four weeks, intramuscular injections with either hCG, initial dose 1500 IE twice weekly (letrozole group) or isotonic saline twice weekly (placebo group) will be added to therapy if plasma total testosterone level has not increased to target plasma level. Following 24 weeks of therapy, all participants will be observed for another 26 weeks without therapy. The study will have one trial center of recruitment: the Department of Endocrinology, Rigshospitalet. Following participation in the study, all participants will be offered a referral to an endocrine outpatient clinic if they still display clinical and biochemical signs of male hypogonadism.</em></p><p><em></em></p><p><em>A healthy group of 30 young lean eugonadal men, who have never used AAS, will be enrolled as control participants and undergo a screening visit and one visit including the same procedures as the screening and randomization visits.</em></p><p></p><p><strong>Primary Outcome Measures :</strong></p><ol> <li data-xf-list-type="ol"><em><em>Change in plasma total testosterone concentration after 24 weeks from baseline [ Time Frame: 24 weeks ]</em></em></li> </ol><p></p><p><strong>Secondary Outcome Measures :</strong></p><ol> <li data-xf-list-type="ol"><em><em>Number of participants who adhere to AAS cessation after 24 and 50 weeks from baseline [ Time Frame: 24 and 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in total plasma testosterone concentration after 50 weeks from baseline [ Time Frame: 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in plasma total testosterone secretion in response to hCG stimulation after 24 and 50 weeks from baseline [ Time Frame: 24 and 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in basal plasma pituitary gonadotropins, LH and FSH, after 24 and 50 weeks from baseline [ Time Frame: 24 and 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in secretion of plasma pituitary gonadotropins, LH and FSH, in response to GnRH stimulation after 24 and 50 weeks from baseline [ Time Frame: 24 and 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in sperm count after 24 and 50 weeks from baseline [ Time Frame: 24 and 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in sperm motility after 24 and 50 weeks from baseline [ Time Frame: 24 and 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in sperm morphology after 24 and 50 weeks from baseline [ Time Frame: 24 and 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in sperm acrosome reaction after 24 and 50 weeks from baseline [ Time Frame: 24 and 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in sperm DNA fragmenting after 24 and 50 weeks from baseline [ Time Frame: 24 and 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in testicular size assessed using ultrasound after 24 and 50 weeks [ Time Frame: 24 and 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in questionnaire score IIEF (erectile function and libido) from baseline and after 24 and 50 weeks [ Time Frame: 24 and 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in questionnaire score ADAM (hypogonadism) from baseline and after 24 and 50 weeks [ Time Frame: 24 and 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in questionnaire score of Major Depression Inventory (MDI) (depression) from baseline and after 24 and 50 weeks [ Time Frame: 24 and 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in questionnaire score of (GAD7) (anxiety) from baseline and after 24 and 50 weeks [ Time Frame: 24 and 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in questionnaire score of Buss-Perry Aggression scale (BPA) (hostility and aggression) from baseline and after 24 and 50 weeks [ Time Frame: 24 and 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in questionnaire score of COBRA (Cognitive complaints in bipolar disorder rating assessment) from baseline and after 24 and 50 weeks [ Time Frame: 24 and 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in questionnaire score of the Health Assessment Short Form-36 questionnaire from baseline and after 24 and 50 weeks [ Time Frame: 24 and 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in questionnaire score of Body-Q 349 (Perception of own body) from baseline and after 24 and 50 weeks [ Time Frame: 24 and 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in questionnaire score of the Inventory of Interpersonal Problems 32-item (IIP32) from baseline and after 24 and 50 weeks [ Time Frame: 24 and 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in myocardial function assessed by myocardial flow reserve (mL/min/gr) by Rb-82 PET from baseline and after 24 and 50 weeks [ Time Frame: 24 and 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in cardiac systolic function was assessed using left ventricular ejection fraction (LVEF) obtained using echocardiography and 24 and 50 weeks from baseline. [ Time Frame: 24 and 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in cardiac systolic function was assessed using left ventricular global longitudinal strain (GLS) obtained using echocardiography and 24 and 50 weeks from baseline. [ Time Frame: 24 and 50 weeks ]</em></em></li> <li data-xf-list-type="ol"><em><em>Change in cardiac structure (left ventricular mass) obtained using echocardiography and 24 and 50 weeks from baseline. [ Time Frame: 24 and 50 weeks ]</em></em></li> </ol></blockquote><p></p>
[QUOTE="madman, post: 248747, member: 13851"] [URL unfurl="true"]https://clinicaltrials.gov/ct2/show/NCT05205837[/URL] [HEADING=2]A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial[/HEADING] [B]Brief Summary[/B] [I]The overall objective of this randomized trial is to investigate the effects of treatment of AAS- induced male hypogonadism with combined therapy of letrozole and hCG compared with placebo on reproductive hormone levels, adherence to cessation of AAS use, fertility, cardiac function, and quality of life.[/I] [B]Detailed Description[/B] [I]A randomized, double-blinded, clinical, placebo-controlled trial enrolling 60 male illicit AAS users with documented AAS-induced hypogonadism after a period > 12 weeks of AAS cessation or a negative urine AAS doping test. Participants will be randomized to two study groups; 24 weeks of treatment with either tablet letrozole (femar®) initial dose of 2.5 mg each day versus tablet placebo. After an initial treatment period of four weeks, intramuscular injections with either hCG, initial dose 1500 IE twice weekly (letrozole group) or isotonic saline twice weekly (placebo group) will be added to therapy if plasma total testosterone level has not increased to target plasma level. Following 24 weeks of therapy, all participants will be observed for another 26 weeks without therapy. The study will have one trial center of recruitment: the Department of Endocrinology, Rigshospitalet. Following participation in the study, all participants will be offered a referral to an endocrine outpatient clinic if they still display clinical and biochemical signs of male hypogonadism. A healthy group of 30 young lean eugonadal men, who have never used AAS, will be enrolled as control participants and undergo a screening visit and one visit including the same procedures as the screening and randomization visits.[/I] [B]Primary Outcome Measures :[/B] [LIST=1] [*][I][I]Change in plasma total testosterone concentration after 24 weeks from baseline [ Time Frame: 24 weeks ][/I][/I] [/LIST] [B]Secondary Outcome Measures :[/B] [LIST=1] [*][I][I]Number of participants who adhere to AAS cessation after 24 and 50 weeks from baseline [ Time Frame: 24 and 50 weeks ][/I][/I] [*][I][I]Change in total plasma testosterone concentration after 50 weeks from baseline [ Time Frame: 50 weeks ][/I][/I] [*][I][I]Change in plasma total testosterone secretion in response to hCG stimulation after 24 and 50 weeks from baseline [ Time Frame: 24 and 50 weeks ][/I][/I] [*][I][I]Change in basal plasma pituitary gonadotropins, LH and FSH, after 24 and 50 weeks from baseline [ Time Frame: 24 and 50 weeks ][/I][/I] [*][I][I]Change in secretion of plasma pituitary gonadotropins, LH and FSH, in response to GnRH stimulation after 24 and 50 weeks from baseline [ Time Frame: 24 and 50 weeks ][/I][/I] [*][I][I]Change in sperm count after 24 and 50 weeks from baseline [ Time Frame: 24 and 50 weeks ][/I][/I] [*][I][I]Change in sperm motility after 24 and 50 weeks from baseline [ Time Frame: 24 and 50 weeks ][/I][/I] [*][I][I]Change in sperm morphology after 24 and 50 weeks from baseline [ Time Frame: 24 and 50 weeks ][/I][/I] [*][I][I]Change in sperm acrosome reaction after 24 and 50 weeks from baseline [ Time Frame: 24 and 50 weeks ][/I][/I] [*][I][I]Change in sperm DNA fragmenting after 24 and 50 weeks from baseline [ Time Frame: 24 and 50 weeks ][/I][/I] [*][I][I]Change in testicular size assessed using ultrasound after 24 and 50 weeks [ Time Frame: 24 and 50 weeks ][/I][/I] [*][I][I]Change in questionnaire score IIEF (erectile function and libido) from baseline and after 24 and 50 weeks [ Time Frame: 24 and 50 weeks ][/I][/I] [*][I][I]Change in questionnaire score ADAM (hypogonadism) from baseline and after 24 and 50 weeks [ Time Frame: 24 and 50 weeks ][/I][/I] [*][I][I]Change in questionnaire score of Major Depression Inventory (MDI) (depression) from baseline and after 24 and 50 weeks [ Time Frame: 24 and 50 weeks ][/I][/I] [*][I][I]Change in questionnaire score of (GAD7) (anxiety) from baseline and after 24 and 50 weeks [ Time Frame: 24 and 50 weeks ][/I][/I] [*][I][I]Change in questionnaire score of Buss-Perry Aggression scale (BPA) (hostility and aggression) from baseline and after 24 and 50 weeks [ Time Frame: 24 and 50 weeks ][/I][/I] [*][I][I]Change in questionnaire score of COBRA (Cognitive complaints in bipolar disorder rating assessment) from baseline and after 24 and 50 weeks [ Time Frame: 24 and 50 weeks ][/I][/I] [*][I][I]Change in questionnaire score of the Health Assessment Short Form-36 questionnaire from baseline and after 24 and 50 weeks [ Time Frame: 24 and 50 weeks ][/I][/I] [*][I][I]Change in questionnaire score of Body-Q 349 (Perception of own body) from baseline and after 24 and 50 weeks [ Time Frame: 24 and 50 weeks ][/I][/I] [*][I][I]Change in questionnaire score of the Inventory of Interpersonal Problems 32-item (IIP32) from baseline and after 24 and 50 weeks [ Time Frame: 24 and 50 weeks ][/I][/I] [*][I][I]Change in myocardial function assessed by myocardial flow reserve (mL/min/gr) by Rb-82 PET from baseline and after 24 and 50 weeks [ Time Frame: 24 and 50 weeks ][/I][/I] [*][I][I]Change in cardiac systolic function was assessed using left ventricular ejection fraction (LVEF) obtained using echocardiography and 24 and 50 weeks from baseline. [ Time Frame: 24 and 50 weeks ][/I][/I] [*][I][I]Change in cardiac systolic function was assessed using left ventricular global longitudinal strain (GLS) obtained using echocardiography and 24 and 50 weeks from baseline. [ Time Frame: 24 and 50 weeks ][/I][/I] [*][I][I]Change in cardiac structure (left ventricular mass) obtained using echocardiography and 24 and 50 weeks from baseline. [ Time Frame: 24 and 50 weeks ][/I][/I] [/LIST] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
Therapy With Letrozole and hCG in Male Hypogonadism Induced by Illicit Use of AAS
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top